{
  "nctId": "NCT03896009",
  "briefTitle": "Maximizing Outcomes in Treating Acute Migraine",
  "officialTitle": "MOMENTUM: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults",
  "protocolDocument": {
    "nctId": "NCT03896009",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-01-16",
    "uploadDate": "2022-12-07T23:53",
    "size": 822393,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03896009/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 1594,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-03-04",
    "completionDate": "2019-12-10",
    "primaryCompletionDate": "2019-12-10",
    "firstSubmitDate": "2019-03-15",
    "firstPostDate": "2019-03-29"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Has an established diagnosis of migraine with or without aura.\n* Has experienced an inadequate response to prior acute treatments.\n\nKey Exclusion Criteria:\n\n* Has previously received any investigational drug or device or investigational therapy within 30 days before Screening.\n* Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Subjects Reporting Headache Pain Freedom",
        "description": "Absence of headache pain. AXS-07 vs Placebo.",
        "timeFrame": "Hour 2 following dose administration"
      },
      {
        "measure": "Percentage of Subjects With Absence of Most Bothersome Symptom",
        "description": "Absence of most bothersome symptom, defined at the onset of migraine. AXS-07 vs Placebo.",
        "timeFrame": "Hour 2 following dose administration"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:53.784Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}